Covering sell-side analysts are estimating company growth for next year to be 0.60%.
Shares of Cara Therapeutics (NDAQ:CARA) opened at 18.04 on Friday. Cara Therapeutics Inc has a 12 month low of $4.35 and a 12 month high of $18.13. The company has a 50-day moving average of $25.92 and a 200 day moving average of $27.01. The company's market cap is $492.17 million. "Reiterates "Market Perform" Rating for Cara Therapeutics Inc (CARA)" was originally posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and republished in violation of global trademark and copyright legislation.
CARA has been the subject of several analyst reports. CIBC dropped their price target on shares of Cara Operations from C$29.00 to C$28.00 in a research note on Friday, November 11th. For the past month, Cara Therapeutics, Inc.'s stock has been 9.40%, 100.44% for the last quarter, 232.84% for the past six months and 219.86% for the past 52 weeks. Scotiabank restated an "outperform" rating and set a $32.00 target price on shares of Cara Therapeutics in a research report on Thursday, November 24th. Cara Therapeutics has an average rating of "Buy" and a consensus price target of $22.77.
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities created to alleviate pain and pruritus by focusing on kappa opioid receptors.